Research and development of new Chinese materia medica for treatment of refractory hematopathy by establishment and application of multiple technique platforms

Gao Rui-lan

doi:10.1007/s11655-007-0095-8

Your Location：

Home >

Browse articles >

Research and development of new Chinese materia medica for treatment of refractory hematopathy by establishment and application of multiple technique platforms

Updated：2021-08-27

- Research and development of new Chinese materia medica for treatment of refractory hematopathy by establishment and application of multiple technique platforms
- Chinese Journal of Integrative Medicine Vol. 13, Issue 2, Pages: 95-97(2007)
- Affiliations：
  
  Institute of Hematology, The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine,Hangzhou,China
- Author bio：
- Funds：
  
  Supported by Australia-China Links Program sponsored by IDP Education Australia (No. II-8), the National Natural Science Foundation of China (No. 30070933), the Natural Science Foundation of Zhejiang Province as the key project (No. DZ007), and State Administration of TCM of China (No. 972025).
- DOI：10.1007/s11655-007-0095-8
  CLC：
- Published：2007，
Scan for full text
Gao, Rl. Research and development of new Chinese materia medica for treatment of refractory hematopathy by establishment and application of multiple technique platforms., Chin. J Integ. Med. 13, 95–97 (2007). https://doi.org/10.1007/s11655-007-0095-8

Gao Rui-lan. Research and development of new Chinese materia medica for treatment of refractory hematopathy by establishment and application of multiple technique platforms. [J]. Chinese Journal of Integrative Medicine 13(2):95-97(2007)
Gao, Rl. Research and development of new Chinese materia medica for treatment of refractory hematopathy by establishment and application of multiple technique platforms., Chin. J Integ. Med. 13, 95–97 (2007). https://doi.org/10.1007/s11655-007-0095-8 DOI：

Gao Rui-lan. Research and development of new Chinese materia medica for treatment of refractory hematopathy by establishment and application of multiple technique platforms. [J]. Chinese Journal of Integrative Medicine 13(2):95-97(2007) DOI： 10.1007/s11655-007-0095-8.

摘要

Abstract

关键词

aplastic anemiaGinsenosidesIdiopathic Thrombocytopenic PurpuraPanax GinsengExtracellular Signal Regulation Protein Kinase

Keywords

aplastic anemiaGinsenosidesIdiopathic Thrombocytopenic PurpuraPanax GinsengExtracellular Signal Regulation Protein Kinase

references

Gao RL, Xu CL, Jin JM, et al. The effects of total saponins of panax ginseng on hematopoietic progenitor cells in healthy humans and aplastic anemia patients. Chin J Integr Tradit West Med 1995; 1(1): 39–42.

Gai Y, Gao RL, Niu YP, et al. Effect of panax notoginsenosides on the proliferation of hematopoietic progenitor cells in mice with immune-mediated aplastic anemia. Chin J Integr Tradit West Med 2003; 23(9): 680–683.

Gao RL, Jin JM, Chong BH, et al. The study of total saponins of panax ginseng in human hematopoiesis. J Zhejiang Coll Tradit Chin Med 1998; 22(6): 37–38.

Zheng YH, Gao RL, Zhu DY, et al. Proliferation of hematopoietic progenitor cells from human bone marrow induced by panax notoginosides. Chin J Integr Tradit West Med Intens Crit Care 2003; 10(3): 135–137.

Jin JM, Tao H, Gao RL, et al. Effect of ginsenosides on proliferation and differentiation of human CD34+ hematopoietic stem/progenitor cells. Chin J Integr Tradit West Med 2000; 20(9): 673–676.

Gao RL, Qian XD, Ma K, et al. Panax notoginosides promotes proliferation and differentiation of human CD34+ hematopoietic stem/progenitor cells. Stem Cell Cell Ther 2003; 1(3): 38–42.

Gao RL, Wu CQ, Chong Benghock, et al. The intracellular signaling pathway initiated by ginsenosides in hematopoietic cells. Chin J Hematol 1999; 20(6): 292–295.

Gao RL, Wu CQ, Chong Benghock, et al. Ginsenosides stimulate proliferation of human megakaryocytic progenitors by up-regulation of GATA-binding activity. Thromb Haemost 1999; Suppl: 818.

Gao RL, Jin JM, Wu CQ, et al. Ginsenosides stimulate proliferation of human megakaryocytic progenitors through GATA transcription factor. J Clin Hematol 1999; 12(2): 50–54.

Gao RL, Ma FS, Wu CQ, et al. Ginseng saponin for refractory blood diseases and transcription as well as up-regulation of gene controlling hematopoietic cells. Bull Med Res 2002; 31(3): 23–24.

Gao RL, Xu WH, Chen XH, et al. Up-regulation of transcription factors NF-E2, c-Jun and c-Fos of AP-1 family induced by panax notoginosides in hematopoietic cells. J Exp Hematol 2004; 12(1): 16–19.

Gao RL, Xu WH, Lin XJ, et al. Up-regulation of transcription factors GATA-1 and GATA-2 induced by panax notoginosides in hematopoietic cells. Chin J Hematol 2004; 25(5): 281–284.

Gao RL, Xu WH, Chen XH, et al. Up-regulation binding activity of GATA and AP-1 transcription factors initiated by panaxadiol of ginseng in hematopoietic cells. Cell Biol Int 2001; 25(10): 1052–1053.

Qian XD, Ma FS, Gao RL, et al. Efficacy observation of Shengxueling Capsules (total saponins of panax ginseng) in treating chronic aplastic anemia. Zhejiang Clin Med J 2004; 6(11): 952–953.

Shen YP, Zhou YH, Yu RX, et al. Clinical observation of total saponins of panax ginseng in combination with cyclosporin A for treatment of chronic aplastic anemia. J Zhejiang Med 2001; 23(3): 178–179.

Shao KD, Zhou YH, Shen YP, et al. Treatment of 37 patients with refractory idiopathic thrombocytopenic purpura by Shengxueling. Chin J Integr Tradit West Med 2007; 13(1): 33–36.

Zhou YH, Yu RX, Luo XS, et al. Clinical observation of total saponins of panax ginseng in treating neutrophil granulocytopenia. Chin J Integr Tradit West Med 2000; 20(7): 539–540.

FULL TEXT LINK

More>

Views

323

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

The ginseng plants: commercial products and quality assessment

Bone marrow angiogenesis in patients presenting with differential Chinese medicine syndrome: Correlation with the clinico-pathological features of aplastic anemia

Roles and mechanisms of ginseng in protecting heart

Red ginseng for type 2 diabetes mellitus: A systematic review of randomized controlled trials

New achievements in ginseng research and its future prospects

Related Author

No data

Related Institution

Arnold Arboretum, Harvard University

Department of Biology and Chinese Medicinal Material Research Center, The Chinese University of Hong Kong

Institute of Chinese Materia Medica, China Academy of Tradition Chinese Medicine

Department of Hematology, the First Affi liated Hospital, Zhejiang University of Traditional Chinese Medicine

Dongzhimen Hospital, Beijing University of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰